Furthermore, our clinical data revealed a trend toward elevated NPY release in ES patients with metastatic tumors, as well as significantly higher systemic NPY levels in pelvic and axial ES of bone origin [29]. This evidence concerns the gene NPY and metastatic neoplasm.